Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases.

Hand-assisted radical nephroureterectomy Laparoscopic radical nephroureterectomy Open radical nephroureterectomy Robotic radical nephroureterectomy Upper tract urothelial carcinoma

Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 09 06 2019
accepted: 10 11 2019
pubmed: 28 11 2019
medline: 29 1 2021
entrez: 28 11 2019
Statut: ppublish

Résumé

To perform a systematic review and meta-analysis of the literature inherent robotic nephroureterectomy (RNU) and to compare its outcomes with those of other nephroureterectomy (NU) techniques. A systematic literature search was performed up to April 2019 using PubMed, Embase®, and Web of Science. The Preferred Reporting Items for Systematic Review and Meta-analysis Statement was followed for study selection. The following data were extracted for each study: baseline features, surgical outcomes, oncological outcomes, and survival outcomes. Stata® 15.0 was used for statistical analysis. Literature search identified 80 studies eligible for the meta-analysis and overall 87,291 patients were included in the analysis: open NU (ONU; n = 45,601), hand-assisted laparoscopic NU (HALNU; n = 442), laparoscopic NU (LNU n = 31,093), and RNU (n = 10,155). RNU was more likely to be performed in those patients with multifocal tumor location (proportion: 0.19; 95% CI 0.14, 0.24) and high-grade disease (proportion: 0.70; 95% CI 0.53, 0.68). The lowest EBL was recorded in the RNU group (weighted mean (WM) 163.31 mL; 95% CI 88.94, 237.68), whereas the highest was in the ONU group (414.99 mL; 95% CI 378.52, 451.46). Operative time was shorter for ONU (224.98 mL; 95% CI 212.26, 237.69). RNU had lower rate of intraoperative complications (0.02; 95% CI 0.01, 0.05). ONU showed higher odds of transfusions (0.20; 95% CI 0.15, 0.25). LOS was statistically significantly shorter for the RNU group (5.35 days; 95% CI 4.97, 5.82). HALNU seemed to present lower risk of PSM (0.02; 95% CI - 0.01, 0.05), and lower risk of recurrence (0.22; 95% CI 0.15, 0.30), metastasis (0.07; 95% CI 0.05, 0.10), and cancer-related death (0.03; 95% CI 0.01, 0.06). ONU showed the lowest 5 years cancer specific survival (proportion: 0.77; 95% CI 0.74, 0.80). No correlation was found between the surgical technique and recurrence-free and cancer-specific survival. Evidence regarding RNU for the treatment of UTUC is increasing but it remains quite sparse and of low quality. Despite this, RNU seems to be safe, and to offer the advantages of a minimally invasive approach without impairing the oncological outcomes. Nevertheless, ONU, HALNU, and LNU still represent a valid, and commonly used surgical treatment option. As RNU becomes more popular, and concerns related to its use remain, the best surgical technique for NU remains to be determined.

Identifiants

pubmed: 31773242
doi: 10.1007/s00345-019-03020-1
pii: 10.1007/s00345-019-03020-1
doi:

Types de publication

Comparative Study Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

845-852

Commentaires et corrections

Type : CommentIn

Références

Minerva Urol Nefrol. 2018 Jun;70(3):242-251
pubmed: 29392926
Eur Urol Focus. 2019 Mar;5(2):205-223
pubmed: 29154042
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
PLoS One. 2019 Jan 8;14(1):e0210401
pubmed: 30620766
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
BJU Int. 2016 Jun;117(6):954-60
pubmed: 26573216
Rev Urol. 2017;19(1):32-43
pubmed: 28522928
World J Urol. 2017 Mar;35(3):327-335
pubmed: 27043218
Urol Oncol. 2019 Jul;37(7):430-436
pubmed: 30846387
BJU Int. 2014 Jul;114(1):90-7
pubmed: 24053174
World J Urol. 2017 Mar;35(3):379-387
pubmed: 27604375
Urology. 2016 Jun;92:136-9
pubmed: 26970451
Can Urol Assoc J. 2014 Sep;8(9-10):E695-701
pubmed: 25408809
Eur Urol. 2009 Sep;56(3):520-6
pubmed: 19560259
J Laparoendosc Adv Surg Tech A. 2018 Jun;28(6):656-681
pubmed: 29461914
Minerva Urol Nefrol. 2017 Oct;69(5):466-474
pubmed: 28198599
Int J Urol. 2019 Apr;26(4):487-492
pubmed: 30756440
J Endourol. 2019 Apr;33(4):263-273
pubmed: 30793934
Eur Urol. 2014 Oct;66(4):769-77
pubmed: 24661639
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
J Endourol. 2018 Feb;32(2):133-138
pubmed: 29205061
Fertil Steril. 2014 Oct;102(4):939-49
pubmed: 24993800
World J Urol. 2017 Oct;35(10):1541-1547
pubmed: 28247066
Urology. 2011 Aug;78(2):357-64
pubmed: 21680014
Minerva Urol Nefrol. 2019 Jun;71(3):191-200
pubmed: 30654603
Med Decis Making. 2005 Nov-Dec;25(6):646-54
pubmed: 16282215
J Endourol. 2017 Jul;31(7):661-665
pubmed: 28537436
Urology. 2016 Jan;87:216-23
pubmed: 26494291
Eur Urol. 2015 Nov;68(5):868-79
pubmed: 26188393
Int J Surg. 2010;8(5):336-41
pubmed: 20171303

Auteurs

Alessandro Veccia (A)

Division of Urology, VCU Health System, VCU Medical Center, PO Box 980118, Richmond, VA, 23298-0118, USA.
Urology Unit, ASST Spedali Civili Hospital, Department of Medical and Surgical Specialties, Radiological Science, and Public Health, University of Brescia, Brescia, Italy.

Alessandro Antonelli (A)

Urology Unit, ASST Spedali Civili Hospital, Department of Medical and Surgical Specialties, Radiological Science, and Public Health, University of Brescia, Brescia, Italy.

Simone Francavilla (S)

Urology Unit, ASST Spedali Civili Hospital, Department of Medical and Surgical Specialties, Radiological Science, and Public Health, University of Brescia, Brescia, Italy.

Claudio Simeone (C)

Urology Unit, ASST Spedali Civili Hospital, Department of Medical and Surgical Specialties, Radiological Science, and Public Health, University of Brescia, Brescia, Italy.

Georgi Guruli (G)

Division of Urology, VCU Health System, VCU Medical Center, PO Box 980118, Richmond, VA, 23298-0118, USA.

Homayoun Zargar (H)

Department of Surgery, Department of Urology, University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia.

Sisto Perdoná (S)

Uro-Gynecological Department, Fondazione "G. Pascale" IRCCS, Naples, Italy.

Matteo Ferro (M)

Division of Urology, European Institute of Oncology, Milan, Italy.

Giuseppe Carrieri (G)

Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Lance J Hampton (LJ)

Division of Urology, VCU Health System, VCU Medical Center, PO Box 980118, Richmond, VA, 23298-0118, USA.

Francesco Porpiglia (F)

Division of Urology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Riccardo Autorino (R)

Division of Urology, VCU Health System, VCU Medical Center, PO Box 980118, Richmond, VA, 23298-0118, USA. ricautor@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH